Literature DB >> 31073068

A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas.

Paolo Strati1, Loretta J Nastoupil2, Richard E Davis2, Luis E Fayad2, Nathan Fowler2, Fredrick B Hagemeister2, Larry Kwak2, Yasuhiro Oki2, Michael Wang2, Jason Westin2, Charnelle E Ruben2, Emily T Wesson2, Richard Piekarz3, Michelle A Fanale2, Hun Ju Lee4.   

Abstract

Entities:  

Year:  2019        PMID： 31073068      PMCID： PMC6939506          DOI： 10.3324/haematol.2019.220012

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  13 in total

1.  Aurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma.

Authors:  Kelly M Zullo; Yige Guo; Laurence Cooke; Xavier Jirau-Serrano; Michael Mangone; Luigi Scotto; Jennifer E Amengual; Yinghui Mao; Renu Nandakumar; Serge Cremers; Jimmy Duong; Daruka Mahadevan; Owen A O'Connor
Journal:  Clin Cancer Res       Date:  2015-04-15       Impact factor: 12.531

Review 2.  New and emerging HDAC inhibitors for cancer treatment.

Authors:  Alison C West; Ricky W Johnstone
Journal:  J Clin Invest       Date:  2014-01-02       Impact factor: 14.808

3.  Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma.

Authors:  Richard L Piekarz; Robin Frye; H Miles Prince; Mark H Kirschbaum; Jasmine Zain; Steven L Allen; Elaine S Jaffe; Alexander Ling; Maria Turner; Cody J Peer; William D Figg; Seth M Steinberg; Sonali Smith; David Joske; Ian Lewis; Laura Hutchins; Michael Craig; A Tito Fojo; John J Wright; Susan E Bates
Journal:  Blood       Date:  2011-02-25       Impact factor: 22.113

4.  Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108.

Authors:  Paul M Barr; Hongli Li; Catherine Spier; Daruka Mahadevan; Michael LeBlanc; Mansoor Ul Haq; Bryan D Huber; Christopher R Flowers; Nina D Wagner-Johnston; Steven M Horwitz; Richard I Fisher; Bruce D Cheson; Sonali M Smith; Brad S Kahl; Nancy L Bartlett; Jonathan W Friedberg
Journal:  J Clin Oncol       Date:  2015-06-15       Impact factor: 44.544

5.  Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.

Authors:  Jonathan W Friedberg; Daruka Mahadevan; Erin Cebula; Daniel Persky; Izidore Lossos; Amit B Agarwal; Jungah Jung; Richard Burack; Xiaofei Zhou; E Jane Leonard; Howard Fingert; Hadi Danaee; Steven H Bernstein
Journal:  J Clin Oncol       Date:  2013-09-16       Impact factor: 44.544

6.  Dual degradation of aurora A and B kinases by the histone deacetylase inhibitor LBH589 induces G2-M arrest and apoptosis of renal cancer cells.

Authors:  Tai-Lung Cha; Mei-Jen Chuang; Sheng-Tang Wu; Guang-Huan Sun; Sun-Yran Chang; Dah-Shyong Yu; Shih-Ming Huang; Steven Kuan-Hua Huan; Tse-Chou Cheng; Tzu-Ting Chen; Pao-Luo Fan; Pei-Wen Hsiao
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

7.  Inhibitors of histone deacetylases induce tumor-selective cytotoxicity through modulating Aurora-A kinase.

Authors:  Jung-Hyun Park; Hyun-Soon Jong; Sang Gyun Kim; Yeonjoo Jung; Keun-Wook Lee; Ju-Hee Lee; Dae-Kee Kim; Yung-Jue Bang; Tae-You Kim
Journal:  J Mol Med (Berl)       Date:  2007-09-13       Impact factor: 4.599

8.  Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels.

Authors:  Leo Kretzner; Anna Scuto; Pamela M Dino; Claudia M Kowolik; Jun Wu; Patrick Ventura; Richard Jove; Stephen J Forman; Yun Yen; Mark H Kirschbaum
Journal:  Cancer Res       Date:  2011-04-18       Impact factor: 12.701

9.  Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses.

Authors:  Bertrand Coiffier; Barbara Pro; H Miles Prince; Francine Foss; Lubomir Sokol; Matthew Greenwood; Dolores Caballero; Franck Morschhauser; Martin Wilhelm; Lauren Pinter-Brown; Swaminathan Padmanabhan Iyer; Andrei Shustov; Tina Nielsen; Jean Nichols; Julie Wolfson; Barbara Balser; Steven Horwitz
Journal:  J Hematol Oncol       Date:  2014-01-23       Impact factor: 17.388

Review 10.  The aurora kinases in cell cycle and leukemia.

Authors:  B Goldenson; J D Crispino
Journal:  Oncogene       Date:  2014-03-17       Impact factor: 9.867
View more
  7 in total

1.  Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies.

Authors:  Tanya Siddiqi; Paul Frankel; Jan H Beumer; Brian F Kiesel; Susan Christner; Chris Ruel; Joo Y Song; Robert Chen; Kevin R Kelly; Sikander Ailawadhi; Paul Kaesberg; Leslie Popplewell; Sandrine Puverel; Richard Piekarz; Stephen J Forman; Edward M Newman
Journal:  Leuk Lymphoma       Date:  2019-10-16

2.  Molecularly targeted therapies for relapsed and refractory peripheral T-cell lymphomas.

Authors:  Zachary D Epstein-Peterson; Steven M Horwitz
Journal:  Semin Hematol       Date:  2021-03-03       Impact factor: 3.851

Review 3.  Biomarker-driven management strategies for peripheral T cell lymphoma.

Authors:  Erin Mulvey; Jia Ruan
Journal:  J Hematol Oncol       Date:  2020-05-24       Impact factor: 17.388

Review 4.  Novel targeted therapies of T cell lymphomas.

Authors:  Katarzyna Iżykowska; Karolina Rassek; Dorota Korsak; Grzegorz K Przybylski
Journal:  J Hematol Oncol       Date:  2020-12-31       Impact factor: 17.388

5.  A toolbox for class I HDACs reveals isoform specific roles in gene regulation and protein acetylation.

Authors:  Lena Hess; Verena Moos; Arnel A Lauber; Wolfgang Reiter; Michael Schuster; Natascha Hartl; Daniel Lackner; Thorina Boenke; Anna Koren; Paloma M Guzzardo; Brigitte Gundacker; Anna Riegler; Petra Vician; Claudia Miccolo; Susanna Leiter; Mahesh B Chandrasekharan; Terezia Vcelkova; Andrea Tanzer; Jun Qi Jun; James Bradner; Gerald Brosch; Markus Hartl; Christoph Bock; Tilmann Bürckstümmer; Stefan Kubicek; Susanna Chiocca; Srividya Bhaskara; Christian Seiser
Journal:  PLoS Genet       Date:  2022-08-22       Impact factor: 6.020

Review 6.  The Future of Combination Therapies for Peripheral T Cell Lymphoma (PTCL).

Authors:  Helen Ma; Ardy Davarifar; Jennifer E Amengual
Journal:  Curr Hematol Malig Rep       Date:  2018-02       Impact factor: 4.213

7.  CCNB2 and AURKA overexpression may cause atypical mitosis in Japanese cortisol-producing adrenocortical carcinoma with TP53 somatic variant.

Authors:  Akira Ikeya; Mitsuko Nakashima; Miho Yamashita; Keisuke Kakizawa; Yuta Okawa; Hirotomo Saitsu; Shigekazu Sasaki; Hironobu Sasano; Takafumi Suda; Yutaka Oki
Journal:  PLoS One       Date:  2020-04-14       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.